Clinical Study Of Atorvastatin In Treatment Of Progressive Cerebral Infarction

Objective: The change of the content of serum TC,TG,LDL,interleukin 6, TNFa, and GSH, MDA in patients with oral atorvastatin treatment through comparative analysis of ischemic stroke, etiology for patients with progressive cerebral diseases, and provide a scientific support for treatment.Methods:1 Research methodsSixty patients with progressive cerebral infarction patients were divided into two groups,experimental group and control group with 30 cases in each group, the control group according to the progressive cerebral infarction therapy is normal, while the experimental group in the control based on the combined with atorvastatin(country medicine accurate H19990258,manufacturers: Pfizer Inc), taking the method for20mg oral, 1 times/day, the treatment period of 2 weeks. Clinical data were collected in accordance with the conditions of patients, includingpatients age, gender, body weight, cardiovascular and cerebrovascular disease duration,height, BMI(body mass index), diastolic blood pressure, systolic blood pressure and other basic clinical data. Experiments were performed 1 and 2 weeks respectively to detect changes in twogroups of patients the serum levels of TC, TG,LDL, interleukin 6, TNFa, IL-10 and GSH, MDAand other biochemical indexes.2 The statistical methodThe data processing and analysis by SPSS16.0 statistical software for statistical analysis, count data using analysis of four exact probability method and X2 test statistics, set the P<0.05 as the difference between the two groups was significant.Result:1 After 1 weeks of treatment, subjects in the experimental group TC, TG,LDL levels were significantly lower than those in the control group(P<0.05). After the 2 weeks of treatment, the experimental group subjects TC, TG,LDL level was still significantly lower than the control group(P<0.05);2 The experimental group patients after third days, seventh days and fourteenth days of serum interleukin-6 levels were significantly lower than the content of the first days of serum interleukin 6(P<0.05) after admission, after seventh days and 14 days, the experimental group serum interleukin-6 levels were significantly lower than those of control group(P<0.05);3 The experimental group subjects in the atorvastatin a week after treatment, the serum GSH content was significantly higher than the control group(P<0.05), MDA content was significantlylower than that of the control group(P<0.05).Conclusions:1 Atorvastatin can significantly decrease the blood lipid levels in patients with progressivecerebral infarction;2 Atorvastatin can reduce the content of inflammatory cytokines in sera of patients withprogressive cerebral infarction;3 Atorvastatin can effectively improve the effective concentration in serum of patients withcerebral infarction in GSH, at the same time, decrease the concentration of MDA in serum of patients with;4 Atorvastatin had no effect on the progression of renal function in patients with cerebral infarction.